TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18326590

Group type: EXPERIMENTAL
Intervention: LCT-MCT
Number of subjects: 12

Group type: COMPARATOR
Intervention: LCT
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study: 16579491

Group type: EXPERIMENTAL
Intervention: Linear, slow‐acting AVC hearing aids
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fast‐acting WDRC hearing aids
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: WDRC in two channels
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hybrid with WDRC in low-frequency and AVC in high-frequency channel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All nonlinear fittings
Number of subjects: 50
Study: 14608527

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (Normotensive volunteers)
Number of subjects: 12
Study: 10950060

Group type: EXPERIMENTAL
Intervention: Conversion strategy (immediate conversion from sigmoidoscopy to colonoscopy)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (traditional sigmoidoscopy followed by colonoscopy on a future day)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Physician-reported outcomes
Number of subjects: 235
Study: 8737633

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 400 mg of buflomedil during 4 h of dialysis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of buflomedil in six other patients maintained on intermittent hemodialysis (3 per week) for 4 weeks
Number of subjects: 10
Study: 1350365

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Albuterol (200 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 4032130

Group type: EXPERIMENTAL
Intervention: Diet plus exercise (supervised exercise program, 3 times a week, walking or running 3 miles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 0
Study: 31851170

Group type: EXPERIMENTAL
Intervention: 2% articaine solution
Number of subjects: 43

Group type: COMPARATOR
Intervention: 2% lidocaine solution
Number of subjects: 43
Study: 30152537

Group type: EXPERIMENTAL
Intervention: Nurse case management intervention
Number of subjects: 70
Study: 27581655

Group type: EXPERIMENTAL
Intervention: EPI smartphone application (EPI app) and reminder text messages
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual procedures and text messages
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: EPI smartphone application (EPI app)
Number of subjects: 32
Study: 24525598

Group type: EXPERIMENTAL
Intervention: Icodextrin-based dialysis solution (ICO group)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Glucose-based dialysis fluid (GLU group)
Number of subjects: 59
Study: 22889955

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (RLX) (60 mg/day) plus SOC (PegIFNα2a 180 μg/week and RBV 600‐1,000 mg/day)
Number of subjects: 123

Group type: COMPARATOR
Intervention: SOC only (PegIFNα2a 180 μg/week and RBV 600‐1,000 mg/day)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (RLX) plus SOC in patients with IL28B TT
Number of subjects: 123

Group type: COMPARATOR
Intervention: SOC only in patients with IL28B TT
Number of subjects: 123
Study: 20233275

Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil ODT on demand
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 18060266

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ion-releasing composite
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Light-cured composite resin (Z-100)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Light-cured, fluoride-containing composite resin (Heliomolar)
Number of subjects: 50
Study: 16100448

Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoids (fluticasone propionate 1,000 microgram/day) for 4 weeks
Number of subjects: 60
Study: 12708095

Group type: EXPERIMENTAL
Intervention: Short monophasic form
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Biphasic form
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Long monophasic form
Number of subjects: 29
Study: 10084469

Group type: EXPERIMENTAL
Intervention: Salmeterol powder (50 microg) twice daily for 52 weeks
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study: 7736395

Group type: EXPERIMENTAL
Intervention: Invitation to screening for women aged 40-74 years
Number of subjects: 133065

Group type: EXPERIMENTAL
Intervention: Invitation to screening for women aged 50-74 years
Number of subjects: 133065

Group type: EXPERIMENTAL
Intervention: Invitation to screening for women aged 40-49 years
Number of subjects: 133065

Group type: EXPERIMENTAL
Intervention: Annual screening regime for women aged 40-49 years
Number of subjects: 133065
Study: 2202792

Group type: COMPARATOR
Intervention: 10 U/mL heparin (H)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 10 U/mL heparin and 25 micrograms/mL vancomycin (H-V)
Number of subjects: 45
Study: 375172

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 31201957

Group type: EXPERIMENTAL
Intervention: Krill oil (KO) supplementation (5 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fish oil (FO) supplementation (5 g)
Number of subjects: 10
Study: 28431420

Group type: EXPERIMENTAL
Intervention: Generative Retrieval (GR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard Practice (SP)
Number of subjects: 30
Study: 25869324

Group type: EXPERIMENTAL
Intervention: High-dose ibuprofen (HDI)
Number of subjects: 72
Study: 23987561

Group type: EXPERIMENTAL
Intervention: EMDR (Eye Movement Desensitization and Reprocessing)
Number of subjects: 40

Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 40
Study: 21825007

Group type: EXPERIMENTAL
Intervention: Nocodazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nocodazole combined with dexamethasone
Number of subjects: 0
Study: 19214599

Group type: EXPERIMENTAL
Intervention: Deep extensor muscle‐preserving laminoplasty (MP group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional open‐door laminoplasty (CL group)
Number of subjects: 84
Study: 16442901

Group type: EXPERIMENTAL
Intervention: Exercise training for 12 weeks
Number of subjects: 152

Group type: COMPARATOR
Intervention: Health education (control)
Number of subjects: 152
Study: 15284085

Group type: EXPERIMENTAL
Intervention: Oral estrogen (0.625 mg per day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (100 microg per day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 11415918

Group type: EXPERIMENTAL
Intervention: 1T bismuth-coated latex shielding
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2T bismuth-coated latex shielding
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3T bismuth-coated latex shielding
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control measurements (no shielding)
Number of subjects: 30
Study: 9113970

Group type: EXPERIMENTAL
Intervention: Standard fiber-optic phototherapy
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Large fiber-optic phototherapy
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Double fiber-optic phototherapy
Number of subjects: 171

Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 171
Study: 8214918

Group type: EXPERIMENTAL
Intervention: 8% CO2 inhalation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2, 4, 6% CO2 inhalation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (term infants and adults)
Number of subjects: 24
Study: 3512589

Group type: EXPERIMENTAL
Intervention: Rehousing in local authority accommodation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31826183

Group type: EXPERIMENTAL
Intervention: 5 mg/kg of caffeine (CAF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5 mg/kg of cellulose as a placebo (PLA)
Number of subjects: 20
Study: 29791677

Group type: EXPERIMENTAL
Intervention: Monthly medical visits with provision of insulin pens and strips for blood glucose measurement, including insulin pen, refills of Neutral Protamine Hagedorn and regular insulin, needles for the pen, blood glucose meter, and capillary blood glucose tests (three tests/day) for six months.
Number of subjects: 45
Study: 25490991

Group type: EXPERIMENTAL
Intervention: Combined non-noxious and noxious stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noxious stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-noxious stimulation
Number of subjects: 0
Study: 25000665

Group type: EXPERIMENTAL
Intervention: Clinpro XT Varnish (VXT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Gluma Dentin Desensitizer (Gluma)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (warm water)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Comparison between VXT and Gluma
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Comparison between VXT and placebo
Number of subjects: 31
Study: 22333849

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (4 doses of 20 mg at 1-month intervals)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nontreatment (no medicine)
Number of subjects: 21
Study: 20102447

Group type: EXPERIMENTAL
Intervention: 4-mg silodosin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 18336918

Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator (Interpersonal psychotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CGT (Complicated Grief Therapy)
Number of subjects: 0
Study: 15901743

Group type: EXPERIMENTAL
Intervention: 5 mg IM ziprasidone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 10 mg IM ziprasidone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 20 mg IM ziprasidone
Number of subjects: 36

Group type: COMPARATOR
Intervention: 5 mg IV ziprasidone
Number of subjects: 36

Group type: COMPARATOR
Intervention: 20 mg oral ziprasidone
Number of subjects: 36
Study: 11828903

Group type: EXPERIMENTAL
Intervention: Radial keratotomy (RK)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 96
Study: 10637713

Group type: EXPERIMENTAL
Intervention: roxatidine 75 mg hs for 8 weeks
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: roxatidine 75 mg hs for 8 weeks + metronidazole 250 mg and amoxicillin 250 mg qid for 1 week on the 3rd week
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Mylanta (20 ml qid for 8 weeks)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Mylanta (20 ml qid for 8 weeks) + metronidazole 250 mg and amoxicillin 250 mg qid for 1 week on the 3rd week
Number of subjects: 83
Study: 7706829

Group type: EXPERIMENTAL
Intervention: Antimony plus interferon-gamma (IFN-gamma)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Antimony alone
Number of subjects: 31
Study: 2036818

Group type: EXPERIMENTAL
Intervention: 5 mg/kg caffeine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 10 mg/kg caffeine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7317996

Group type: EXPERIMENTAL
Intervention: In-patient treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day center treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Walk-in clinic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31067997

Group type: EXPERIMENTAL
Intervention: Nutrition education combined with a supplementary porridge intervention for 3 months
Number of subjects: 204
Study: 28290229

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (170 units)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline injection (placebo)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (after crossover from placebo)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Number of subjects: 20
Study: 25233911

Group type: EXPERIMENTAL
Intervention: Additive solution-7 (AS-7)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control solution AS-1
Number of subjects: 180
Study: 22981094

Group type: EXPERIMENTAL
Intervention: Submucosal 2 mL 100 mg tramadol injection (group T)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Normal saline solution (group P)
Number of subjects: 52
Study: 22635164

Group type: EXPERIMENTAL
Intervention: 1000 mg testosterone undecanoate (intramuscular injection at weeks 0, 6, 18, 30, and 42)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (intramuscular injection at weeks 0, 6, 18, 30, and 42)
Number of subjects: 120
Study: 19135839

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound imaging (CEUS) with a dose of 2.4 mL of a second-generation contrast agent.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Unenhanced ultrasound imaging (US).
Number of subjects: 84
Study: 17690122

Group type: EXPERIMENTAL
Intervention: Fluticasone (16 puffs; 4,000 microg.day(‐1))
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prednisone (30 mg.day(‐1))
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (placebo for fluticasone)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (placebo for prednisone)
Number of subjects: 45
Study: 16212139

Group type: EXPERIMENTAL
Intervention: Risedronate at 5 mg/d
Number of subjects: 2483

Group type: EXPERIMENTAL
Intervention: Risedronate at 15 mg/d
Number of subjects: 2483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2483

Group type: EXPERIMENTAL
Intervention: Risedronate at 35 mg once weekly
Number of subjects: 2483

Group type: EXPERIMENTAL
Intervention: Risedronate at 50 mg once weekly
Number of subjects: 2483
Study: 11847044

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography
Number of subjects: 120
Study: 11045061

Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Halothane (group H, n = 20)
Number of subjects: 40
Study: 7673013

Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy
Number of subjects: 54
Study: 1981318

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bopindolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atenolol and Bopindolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 12
Study: 7025315

Group type: EXPERIMENTAL
Intervention: Subtotal gastric exclusion (bypass)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Modified Gomez gastric partitioning
Number of subjects: 100
Study: 28221821

Group type: EXPERIMENTAL
Intervention: Blueberry supplementation for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 27496698

Group type: EXPERIMENTAL
Intervention: Normal mood at baseline measured with the Beck Anxiety Inventory
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Psychological resource factors (pain self‐efficacy)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Psychological resource factors (satisfaction with life)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Pain catastrophizing
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Fear of movement (kinesiophobia)
Number of subjects: 111
Study: 24937270

Group type: EXPERIMENTAL
Intervention: Active stimulation with random frequency (1-5 Hz)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Active stimulation with 1 Hz
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Active stimulation with 100 Hz
Number of subjects: 38
Study: 22089476

Group type: EXPERIMENTAL
Intervention: ITL10 (10 cm H2O)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ITL15 (15 cm H2O)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ITL20 (20 cm H2O)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 8
Study: 20413077

Group type: EXPERIMENTAL
Intervention: Healthy Choices motivational intervention (4 sessions)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Healthy Choices motivational intervention (at least 2 sessions)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Multidisciplinary specialty care alone (control)
Number of subjects: 186
Study: 19093930

Group type: EXPERIMENTAL
Intervention: Medicare Part D coverage for clopidogrel, proton pump inhibitors (PPIs), warfarin, and statins
Number of subjects: 13032

Group type: COMPARATOR
Intervention: Benzodiazepines (not covered through Part D)
Number of subjects: 13032

Group type: EXPERIMENTAL
Intervention: Medicare Part D coverage for PPIs
Number of subjects: 13032

Group type: EXPERIMENTAL
Intervention: Other study drug classes (warfarin, statins, benzodiazepines)
Number of subjects: 13032
Study: 16928933

Group type: EXPERIMENTAL
Intervention: Retention balloon catheter
Number of subjects: 223

Group type: COMPARATOR
Intervention: Standard tip catheter
Number of subjects: 223
Study: 14641666

Group type: EXPERIMENTAL
Intervention: Polyacid modified resin composites (F‐2000, Hytac, Compoglass F)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer cement (Fuji II LC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer (Ketac‐Fil)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resin composite (Z‐100)
Number of subjects: 30
Study: 10823442

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg orally 1 hour before barium suspension
Number of subjects: 45

Group type: COMPARATOR
Intervention: Metoclopramide 20 mg orally 1 hour before barium suspension
Number of subjects: 45
Study: 8542002

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (100,000 IU oral)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 1838046

Group type: EXPERIMENTAL
Intervention: Ambient temperature at 33 degrees C
Number of subjects: 32
Study: 7065387

Group type: EXPERIMENTAL
Intervention: Haemonetics cell saver
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Re-transfusion of washed packed red cells
Number of subjects: 20
Study: 31550080

Group type: EXPERIMENTAL
Intervention: Mucosal grafts and pedicled flap reconstruction of the neo‐ostium
Number of subjects: 50

Group type: COMPARATOR
Intervention: No mucosal grafts and pedicled flap reconstruction
Number of subjects: 50
Study: 28927475

Group type: EXPERIMENTAL
Intervention: Contact Precautions (CP)
Number of subjects: 3154

Group type: COMPARATOR
Intervention: Standard Precautions (SP)
Number of subjects: 3154
Study: 25486299

Group type: EXPERIMENTAL
Intervention: High-intensity stretching intervention (8 weeks, average of 3.1 sessions per week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 10
Study: 23510792

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (600 ?g)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Oxytocin infusion (20 intravenous units)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 218
Study: 21550561

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study: 19142086

Group type: EXPERIMENTAL
Intervention: Delta sleep-inducing peptide (DSIP) at 25 nmol kg(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Delta sleep-inducing peptide (DSIP) at 50 nmol kg(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Delta sleep-inducing peptide (DSIP) at 100 nmol kg(‐1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study: 16937072

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) during pregnancy, three sessions between week 23 and 30 and one session 6 weeks after delivery, combined with written information
Number of subjects: 264

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 264
Study: 15218330

Group type: EXPERIMENTAL
Intervention: benidipine (4-8 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: nifedipine CR (20-40 mg/day)
Number of subjects: 10
Study: 11523124

Group type: COMPARATOR
Intervention: Method 1 (conventional procedure): oral magnesium citrate followed by glycerin enema.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Method 2 (new procedure): oral magnesium citrate followed by oral picosulfate and bisacodyl suppository.
Number of subjects: 38
Study: 9748048

Group type: EXPERIMENTAL
Intervention: Gabapentin (300 to 2,400 mg/d)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 7820984

Group type: EXPERIMENTAL
Intervention: Intravenous clarithromycin infusion (1.5 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3273863

Group type: EXPERIMENTAL
Intervention: One antacid tablet (experimental)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5 ml of liquid antacid (commercial)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 ml of liquid antacid (commercial)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Two antacid tablets (experimental)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31010090

Group type: EXPERIMENTAL
Intervention: Social support (Reassurance of Worth and Reliable Alliance)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Postnatal depression
Number of subjects: 54
Study: 26960538

Group type: EXPERIMENTAL
Intervention: Gadobutrol at the recommended dose (0.11 mmol/kg body weight)
Number of subjects: 23708

Group type: EXPERIMENTAL
Intervention: Gadobutrol at the recommended dose
Number of subjects: 23708
Study: 25775052

Group type: EXPERIMENTAL
Intervention: Bivalirudin with a post-PCI infusion (n=735)
Number of subjects: 2194

Group type: COMPARATOR
Intervention: Heparin alone (n=729)
Number of subjects: 2194

Group type: COMPARATOR
Intervention: Heparin plus tirofiban (n=730)
Number of subjects: 2194

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 2194

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 2194

Group type: COMPARATOR
Intervention: Heparin plus tirofiban
Number of subjects: 2194